Hormone Therapy and Heart Risk: Does Timing Matter?
Whether hormone therapy helps or hurts your heart may depend heavily on when you start it. In the Women’s Health Initiative, women who began hormone therapy nearer to menopause (their 50s) trended toward lower heart-disease risk in that data, while women who started a decade or more later (their 70s) trended toward higher risk. This is informational, not a recommendation; the decision belongs with your own clinician.
Look at the age-stratified data first Starting near menopause looked protective for the heart; starting a decade or more later did not
Age at initiation appears to change the entire risk-benefit picture for cardiovascular outcomes.
Consider the randomized evidence, not just observational data The ELITE trial randomized women by time since menopause and found estradiol slowed artery-wall thickening in women under 6 years post-menopause, with no effect in women 10+ years out
ELITE was designed specifically to test the timing hypothesis with randomization, which strengthens confidence in the age-related pattern.
Use this as a framework, not a rule Haver describes the group most likely to see benefit outweigh risk as roughly under 60 and within about 10 years of menopause
This framing helps organize the conversation with your clinician, but it is a guideline, not an individual guarantee.
Have the conversation with your clinician Bring your age, years since menopause, and personal and family cardiovascular history to your OB-GYN or a menopause-trained clinician; this is an individual risk-benefit conversation and this page gives no doses
This is an individualized risk-benefit decision that depends on your personal history, and this page intentionally gives no doses.
In the Women’s Health Initiative, age at the start of hormone therapy was linked to markedly different cardiovascular outcomes: lower heart-disease risk for women who started nearer to menopause (their 50s), versus higher risk for those who started a decade or more later (their 70s).
View sources
Is Hormone Therapy After 60 Still on the Table? (Dr. Mary Claire Haver)
Your Heart on Menopause (Dr. Mary Claire Haver)
Hodis et al. - Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE, NEJM 2016)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol is an independent platform. This protocol is based on the publicly available work of Mary Claire Haver and is not created, reviewed, endorsed by, or affiliated with Mary Claire Haver or The Pause Life.
Is this for you
- Women considering hormone therapy near menopause
- Women wondering if it's 'too late' to start hormone therapy
- Anyone who wants the age-stratified evidence before talking to their doctor
- People weighing personal or family cardiovascular history against menopause symptoms
Cautions
- This is an individual decision that belongs with your own clinician; this page gives no doses
- The WHI age-stratification was a subgroup analysis, not the trial’s original primary design, an important caveat on how strongly it should be weighted
- A history of hormone-sensitive cancer changes the calculus entirely and should be discussed directly with your clinician
- Educational only, not medical advice